Korn A, Eichler H G, Fischbach R, Gasic S
Psychopharmacology (Berl). 1986;88(2):153-7. doi: 10.1007/BF00652232.
Moclobemide is a new, short-acting, reversible MAOI, preferentially affecting type A MAO. We have studied the interaction of moclobemide with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Neither tyramine capsules (50 mg) nor cheese and wine meals (65 mg tyramine) produced a significant change in blood pressure and heart rate after single or repeated doses of moclobemide in volunteers. In contrast, after 1 weeks' treatment with tranylcypromine pressure response to cheese and wine meals was severe. Blood pressure sensitivity to IV tyramine was slightly increased (1.5-2 fold; P less than 0.05 versus predrug) during moclobemide treatment in patients and volunteers. This increase was neutralised by concomitant administration of desipramine in volunteers. Amitriptyline was well tolerated when given to patients after or together with moclobemide. In conclusion, moclobemide appears relatively safe with respect to tyramine sensitivity and interaction with tricyclics.
吗氯贝胺是一种新型、短效、可逆性单胺氧化酶抑制剂，对A型单胺氧化酶有优先作用。我们已在健康志愿者和抑郁症患者中研究了吗氯贝胺与酪胺及三环类抗抑郁药之间的相互作用。在志愿者单次或重复服用吗氯贝胺后，50毫克酪胺胶囊或奶酪加葡萄酒餐（含65毫克酪胺）均未使血压和心率发生显著变化。相比之下，在用反苯环丙胺治疗1周后，对奶酪加葡萄酒餐的血压反应很强烈。在患者和志愿者接受吗氯贝胺治疗期间，静脉注射酪胺引起的血压敏感性略有增加（1.5至2倍；与用药前相比P<0.05）。在志愿者中，合用去甲丙咪嗪可消除这种增加。在患者服用吗氯贝胺之后或同时给予阿米替林时，耐受性良好。总之，吗氯贝胺在酪胺敏感性及与三环类药物的相互作用方面似乎相对安全。
